A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome

Psychiatric Genetics

Volumn 20, Issue 1, 2010, Pages 35-38

  Dehning, Sandra ^a   Müller, Norbert ^a   Matz, Judith ^a   Bender, Andreas ^a   Kerle, Irina ^a   Benninghoff, Jens ^a   Musil, Richard ^a   Spellmann, Ilja ^a   Bondy, Brigitta ^a   Möller, Hans Juergen ^a   Riedel, Michael ^a   Zill, Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Genetic; HTR2C; Polymorphisms; Serotonin; Tourette syndrome

Indexed keywords

HTR2C PROTEIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE RELEASE; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ALLELES; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2C; SEX FACTORS; TOURETTE SYNDROME; YOUNG ADULT;

EID: 75149156594     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/YPG.0b013e32833511ce     Document Type: Article

References (23)

1. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113: 296-320.
2. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, et al. (1998). Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 3:61-66. (Pubitemid 28045186)
3. Buckland PR, Hoogendoorn B, Guy CA, Smith SK, Coleman SL, O'Donovan MC (2005). Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry 162:613-615.
4. Cavallini MC, Di BD, Catalano M, Bellodi L (2000). An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome. Psychiatry Res 97:93-100.
5. Chou IC, Tsai CH, Lee CC, Kuo HT, Hsu YA, Li CI, et al. (2004). Association analysis between Tourette's syndrome and dopamine D1 receptor gene in Taiwanese children. Psychiatr Genet 14:219-221.
6. Diaz-Anzaldua A, Joober R, Riviere JB, Dion Y, Lesperance P, Richer F, et al. (2004). Tourette syndrome and dopaminergic genes: a family-based association study in the French Canadian founder population. Mol Psychiatry 9:272-277.
7. Heinz A, Knable MB, Wolf SS, Jones DW, Gorey JG, Hyde TM, et al. (1998). Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology 51:1069-1074.
8. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. (1989). The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566-573.
9. Lee CC, Chou IC, Tsai CH,Wang TR, Li TC, Tsai FJ (2005). Dopamine receptor D2 gene polymorphisms are associated in Taiwanese children with Tourette syndrome. Pediatr Neurol 33:272-276.
10. Marazziti D, Betti L, Giannaccini G, Rossi A, Masala I, Baroni S, et al. (2001). Distribution of [3H]GR65630 binding in human brain postmortem. Neurochem Res 26:187-190.
11. Niesler B, Frank B, Hebebrand J, Rappold G (2005). Serotonin receptor genes HTR3A and HTR3B are not involved in Gilles de la Tourette syndrome. Psychiatr Genet 15:303-304.
12. Ozbay F, Wigg KG, Turanli ET, Asherson P, Yazgan Y, Sandor P, et al. (2006). Analysis of the dopamine beta hydroxylase gene in Gilles de la Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet 141:673-677.
13. Pauls DL, Raymond CL, Stevenson JM, Leckman JF (1991). A family study of Gilles de la Tourette syndrome. Am J Hum Genet 48:154-163.
14. Price RA, Kidd KK, Cohen DJ, Pauls DL, Leckman JF (1985). A twin study of Tourette syndrome. Arch Gen Psychiatry 42:815-820.
15. Reynolds GP, Templeman LA, Zhang ZJ (2005). The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 29:1021-1028.
16. Robertson MM (2008). The prevalence and epidemiology of Gilles de la Tourette syndrome Part 1: the epidemiological and prevalence studies. J Psychosom Res 65:461-472.
17. Robertson MM, Stern JS (2000). Gilles de la Tourette syndrome: symptomatic treatment based on evidence. Eur Child Adolesc Psychiatry 9 (Suppl 1):I60-I75.
18. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, et al. (1995). Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7:169-172.
19. Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL (2006). Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 11:224-226.
20. Wong DF, Brasic JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, et al. (2008). Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo Neurochemistry Study with PET. Neuropsychopharmacology 33:1239-1251.
21. Yoon DY, Rippel CA, Kobets AJ, Morris CM, Lee JE, Williams PN, et al. (2007). Dopaminergic polymorphisms in Tourette syndrome: association with the DAT gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet 144:605-610.
22. Yu L, Nguyen H, Le H, Bloem LJ, Kozak CA, Hoffman BJ, et al. (1991). The mouse 5-HT1C receptor contains eight hydrophobic domains and is X-linked. Brain Res Mol Brain Res 11:143-149.
23. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K (2000). Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 43:373-376.